Stable CR or PR in adult ITP patients after splenectomy failure
. | No. patients in CR or PR . | . | . | Time to remission, mo mean/median (range) . | Duration of remission, mo mean/median (range) . | ||
|---|---|---|---|---|---|---|---|
| Treatment group . | On Rx . | Off Rx . | Total . | . | . | ||
| Group 0 | 0 | 8 | 8 | 74/70.5 (3-143) | 86.6/75.5 (36-191) | ||
| Group 1 | 20 | 23 | 43 | 60.6/37 (1-358) | 66/56 (2-177) | ||
| CS | 10 | 10 | 20 | — | — | ||
| Dn | 1 | 2 | 3 | — | — | ||
| Dn/Pred | 5 | 7 | 12 | — | — | ||
| Dn/Co/Pred | 1 | 0 | 1 | — | — | ||
| Dn/Pred/Vin | 0 | 1 | 1 | — | — | ||
| Dn/Pred/Rit | 1 | 0 | 1 | — | — | ||
| Dn/Co | 0 | 1 | 1 | — | — | ||
| Co | 0 | 2 | 2 | — | — | ||
| Dap | 1 | 0 | 1 | — | — | ||
| IFN/Vin | 1 | 0 | 1 | — | — | ||
| Group 2 | 4 | 11 | 15 | 89.3/70 (11-437) | 52.4/42 (10-212) | ||
| Ctx | 0 | 9 | 9 | — | — | ||
| Az | 1 | 2 | 3 | — | — | ||
| CsA | 3 | 0 | 3 | — | — | ||
| Group 3 | 0 | 9 | 9 | 63.6/34 (19-193) | 51.9/26 (12-176) | ||
| HD-Ctx | 0 | 1 | 1 | — | — | ||
| ComboRx | 0 | 8 | 8 | — | — | ||
| Total | 24 | 51 | 75 | 68.1/46 (1-358) | 64/49 (2-212) | ||
. | No. patients in CR or PR . | . | . | Time to remission, mo mean/median (range) . | Duration of remission, mo mean/median (range) . | ||
|---|---|---|---|---|---|---|---|
| Treatment group . | On Rx . | Off Rx . | Total . | . | . | ||
| Group 0 | 0 | 8 | 8 | 74/70.5 (3-143) | 86.6/75.5 (36-191) | ||
| Group 1 | 20 | 23 | 43 | 60.6/37 (1-358) | 66/56 (2-177) | ||
| CS | 10 | 10 | 20 | — | — | ||
| Dn | 1 | 2 | 3 | — | — | ||
| Dn/Pred | 5 | 7 | 12 | — | — | ||
| Dn/Co/Pred | 1 | 0 | 1 | — | — | ||
| Dn/Pred/Vin | 0 | 1 | 1 | — | — | ||
| Dn/Pred/Rit | 1 | 0 | 1 | — | — | ||
| Dn/Co | 0 | 1 | 1 | — | — | ||
| Co | 0 | 2 | 2 | — | — | ||
| Dap | 1 | 0 | 1 | — | — | ||
| IFN/Vin | 1 | 0 | 1 | — | — | ||
| Group 2 | 4 | 11 | 15 | 89.3/70 (11-437) | 52.4/42 (10-212) | ||
| Ctx | 0 | 9 | 9 | — | — | ||
| Az | 1 | 2 | 3 | — | — | ||
| CsA | 3 | 0 | 3 | — | — | ||
| Group 3 | 0 | 9 | 9 | 63.6/34 (19-193) | 51.9/26 (12-176) | ||
| HD-Ctx | 0 | 1 | 1 | — | — | ||
| ComboRx | 0 | 8 | 8 | — | — | ||
| Total | 24 | 51 | 75 | 68.1/46 (1-358) | 64/49 (2-212) | ||
Patients were arbitrarily divided into treatment groups based on the treatment(s) that resulted in CR or PR. Group 0, spontaneous remission or remission of uncertain origin. Group 1, response to corticosteroids (CS); danazol (Dn) alone or in combination with prednisone (Pred), colchicine (Co), vinblastine (Vin), or rituximab (Rit); colchicine; dapsone (Dap); or vinblastine/interferon (IFN). Group 2, response to oral cyclophosphamide (Ctx); azathioprine (Az), or cyclosporine (CsA) alone or in combination with Pred or mycophenolate-mofetil. Group 3, response to intravenous high-dose cyclophosphamide (HD-Ctx) or combination chemotherapy (ComboRx).
Time to remission refers to time in months from splenectomy to stable CR or PR, either on or off therapy.
Duration of remission refers to time in months during which patients remained in CR or PR, either on or off therapy.
— indicates not determined.